Altaroc
Companies
ScreenPoint
Manager
Fund |
Manager |
Co-invested company
sector
Healthcare
regional split
Europe
vintage
status
Portfolio
category
Positive impact
Insight Partners XII
Insight Partners

ScreenPoint

Co-invested company
ScreenPoint has developed artificial intelligence to improve the early detection of breast cancer by analyzing mammograms.
Employees of ScreenPoint, part of the Private Equity manager's portfolio Insight Partners

ScreenPoint key figures

23
country
+ 5 M
examinations carried out
200
scientific publications in breast imaging and artificial intelligence
200
clinics
Data as at
25/3/26
*Source: Public data from companies’ websites and social media accounts. For more up-to-date information, we invite our investors to view the report made available on their space.

The Altaroc Odyssey 2021 fpci is closed for business.

About ScreenPoint

Netherlands-based ScreenPoint Medical has developed cutting-edge artificial intelligence technology to improve early detection of breast cancer.

Using Machine Learning techniques, it collects and interprets radiological data to provide radiologists with accurate and accessible analysis. This system not only reduces radiologists' workload, but also improves the quality of diagnoses.

Founded in 2014 by Nico Karssemeijer and Michael Brady, specialists in breast imaging, Machine Learning and computer-aided detection, ScreenPoint Medical has assembled a team of experts from the outset to develop a decision-support algorithm. Their main objective is to facilitate early detection of breast cancer in order to improve chances of survival and promote less invasive treatments, with the ultimate goal of saving lives.

ScreenPoint Medical's main product, Transpara Breast AI, has been trained on a large dataset comprising one million images and 15,000 cancer cases from various mammography models and medical centers. The algorithm's results are verified by confirmatory methods such as biopsy. To date, this artificial intelligence has analyzed over 5 million mammograms (2D and 3D) in more than 30 countries, in collaboration with radiologists.

To help interpret the results, ScreenPoint Medical has developed the Transpara Exam Score tool, which assesses cancer risk on a 10-point scale. Clinical research has shown that scores of 1 to 7, indicating a low risk on the scale, have a negative predictive value of 99.97%.

The company is experiencing significant growth, with 67 employees and annual recurring revenues of $13.6 million.

Every year in France, over 50,000 cases of breast cancer are diagnosed, underlining the importance of innovative solutions like those developed by ScreenPoint Medical, while over 4.4 million mammograms are performed for screening purposes.

In the same sector as ScreenPoint

Company videos
No items found.

Discover the new Vintage Altaroc Odyssey 2025

Discover the Vintage Altaroc Horizon

Insight Partners
Odyssey 2021
Odyssey 2021
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Welcome to Altaroc
To provide you with a tailored experience, we invite you to complete your profile.
Your profile
country of tax residence
Select
choosenCountry
Preferred language
Select
choosenLang
Your investor profile
Financial intermediary or Professional investor
Financial advisors, wealth management advisors, private bankers, or any other investment service providers.
Qualified Investor or Altaroc Investor
Experienced Investor or Altaroc Investor
Private investors who have already invested in Altaroc who have a minimum investment capacity of €100,000.
Private investors who have already invested in Altaroc who have a minimum investment capacity of €250,000.
Inexperienced investor
Individual investors with an investment capacity of less than €100,000.
Individual investors with an investment capacity of less than €250,000.
Institutional investor
Pension funds, retirement funds, asset management firms, and single-family offices.
Scroll down to accept General Terms and Conditions
The webpage you are trying to access is not available in your country.